Year: 2026
Type: article
Study design: Clinical Trial
Abstract: Musculoskeletal infections (MSIs), including fracture-related infections (FRIs) and periprosthetic joint infections (PJIs), remain difficult to treat because of biofilm formation and increasing antimicrobial resistance. Bacteriophage therapy (PT) has re-emerged as a promising adjunctive strategy, although prospective clinical evidence remains scarce. Here, we prospectively evaluated adjunctive local PT in 13 patients with refractory MSIs treated within the multidisciplinary PHAGEFORCE framework at University Hospitals Leuven (BE). Following surgery, personalized phage preparations were administered through a closed drain system for 8–10 days alongside systemic antibiotics. Clinical, microbiological, immunological, and genomic data were collected. Four patients with refractory MSIs lacking suitable phages served as a control cohort. Clinical remission was observed in nine of eleven evaluable phage-treated patients (82%), whereas all control patients experienced infection recurrence during follow-up. PT was well tolerated, with no serious adverse reactions or clinically meaningful toxicity. Local phage titers remained detectable throughout therapy despite interpatient variability. Serum-mediated phage neutralization was observed during and after PT, and longitudinal genomic monitoring revealed patient-specific phage dynamics, neither of which was clearly associated with clinical outcome. These findings demonstrate the feasibility and safety of standardized local PT and support further evaluation of this approach in controlled clinical trials. In this prospective study, authors found that personalized adjunctive local phage therapy was feasible and well tolerated in difficult-to-treat musculoskeletal infections, with 9 of 11 evaluable patients achieving remission.
Source: Nature Communications
Authors: Laura Bessems, Louise Sykora, Melissa Depypere, Yves Debaveye, Isabel Spriet, David Devolder, Paul De Munter, Liesbet Henckaerts, Georges Vles, Hazem Wafa, Rob Lavigne, Stefaan Verwimp, Vera Van Noort, Sabrina Green, Maya Merabishvili, Jean-Paul Pirnay, Geert Molenberghs, Jolien Onsea, Willem-Jan Metsemakers
Language: English
Subfield: Virology
Field: Immunology and Microbiology
Domain: Life Sciences
Open Access status: gold
Estimated APC paid: $6,990
Funder: KU Leuven
Award: G2439619780
OpenAlex ID: W7225328481
